Previous Image
Next Image

info heading

info content

IKCC Conference, 6th – 8th April 2017, Warsaw, Poland

3385_de_02_p_1024x7687th International Kidney Cancer Coalition Conference

Warsaw, Poland 6th, 7th & 8th April 2017

 

Our seventh IKCC Conference for kidney cancer patient organisations will be held in Warsaw, Poland on 6th, 7th & 8th April 2017.

Our conference will bring together cancer patient group leaders from around the world to share best practices, exchange experiences and work together to improve the lives of kidney cancer patients wherever they live. Read more

Posted in Homepage Feature | Tagged | Comments Off on IKCC Conference, 6th – 8th April 2017, Warsaw, Poland

Understanding Immuno-Oncology

10-for-IO logoImmuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour.  Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information about immuno-oncology specifically as it applies to renal cell carcinoma. Click here for more information.

Posted in Homepage Feature, Immuno-Oncology, Treatment Options | Tagged , , | Comments Off on Understanding Immuno-Oncology

Sonepcizumab shows promise for metastatic kidney cancer

Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. Read more here

Posted in Clinical Trials, Homepage Feature | Tagged , | Comments Off on Sonepcizumab shows promise for metastatic kidney cancer

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

Dr. Laurescreen-shot-2016-10-18-at-21-03-55nce Albiges, Oncologist, head of the GU Tumor Board at the Gustave Roussy speaking during ESMO 2016 about how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).  Watch the video.

Posted in Homepage Feature, Immuno-Oncology, Treatment Options | Tagged , , | Comments Off on Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer

unknownResults from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more

Posted in Clinical Trials, Homepage Feature | Comments Off on Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer

Sunitinib shown to improve disease-free survival in people with kidney cancer

Results frounknownm the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib  improved disease-free survival in patients with localised kidney cancer  that had been surgically removed; a group considered high-risk for relapse. Read more

Posted in Clinical Trials, Homepage Feature | Tagged | Comments Off on Sunitinib shown to improve disease-free survival in people with kidney cancer